Two Trials Later, Boehringer Abandons ‘Female Viagra’

Boehringer Ingelheim is abandoning development of its so-called “female Viagra” to treat hypoactive sexual desire disorder in premenopausal women following a complete response letter and negative advisory panel vote. “The decision was not made lightly, considering the advanced stage of development,” Andreas Barner, chairman of Boehringer’s board of managing directors, said. The company’s decision was based on the complexity and extent of additional questions that would need to be addressed before approval.
Clinical Trials Advisor